Events Calendar

COPD

1 in 2 COPD patients hospitalised due to an exacerbation may die within 4 years. The prevention of exacerbations should be a key focus in managing COPD patients.

Frequent exacerbations of COPD can cause poor quality of life and a rapid decline in lung function.

In Australia, COPD is the second leading cause of avoidable hospital admissions and remains the fifth leading cause of death.

Asthma

While 2.7 million Australians are affected by asthma, based on international studies it is estimated that 3-10% of these people have severe asthma. This represents between 52,800 and 176,000 people in Australia.

Research shows that up to 1 in 3 patients with asthma remain uncontrolled despite adherence to stepwise management with ICS/LABA.

This meeting will give you the opportunity to understand the role of single inhaler triple therapy in the management of COPD and asthma.

Speaker:

Associate Professor John Brannan, PhD

Associate Professor John Brannan is the Scientific Director in the Department of Respiratory & Sleep Medicine at John Hunter Hospital, Newcastle where his key focus is running the pulmonary function and cardiopulmonary exercise laboratories. He also preforms research in respiratory diseases with a focus in asthma, which included an interest in the bronchial provocation testing as aid to identify both active asthma, exercise-induced bronchoconstriction and chronic cough. He has a strong interest in investigating mechanism of drug treatments in airway diseases.

Learning Objectives

1. Differential diagnosis of COPD and asthma
2. Need for optimising treatment of patients with COPD and asthma currently on ICS/LABA
3. Role of Single Inhaler Triple Therapy in the management of moderate/severe COPD and asthma

Contact:

Daniela Rapattoni

Daniela.x.rapattoni@gsk.com

0412 916 429

Register